A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma.
Phase of Trial: Phase I
Latest Information Update: 21 May 2014
At a glance
- Drugs Sorafenib (Primary)
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 08 Apr 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 May 2012 Additional lead trial centre identified and actual patient number is 47 as reported by ClinicalTrials.gov.
- 02 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.